Production of interleukin-6, tumor necrosis factor a and interleukin-lO in vitro correlates with the clinical immune defect in chrouic hemodialysis patients. In patients with chronic renal failure alterations in monokine production are a common feature. Their clinical relevance has not yet been proven. We show here a correlation between an overproduction of interleukin-(IL)-6 and tumor necrosis factor alpha (1'NFa) upon stimulation with LPS by mononuclear cells in vitro and the clinical grade of immunodeficiency found in these patients. Higher levels of IL-6 and TNFa were correlated with an immunocompromized state, that is, nonresponsiveness to hepatitis B vaccination, whereas patients with a better immune competence showed the same levels of these cytokines as healthy controls. Only the patients with a good immune function showed a high secretion of IL-tO. The feedback mechanism of IL-tO for reducing monokine synthesis seems to be intact in theae patients. Thus the secretion of IL-tO might be regarded as a compensatory mechanism which controls monokine induction by chronic renal failure and hemodialysis treatment. Immunocompromized patients who are unresponsive to hepatitis B vaccination seem to be unable to enhance IL-b synthesis for control of monokine overproduction. This results in higher levels of IL-6 and TNFa that might be involved in the pathogenesis of reduced immune defense.
ciency in most patients. This is characterized by impaired efficacy of vaccinations, such as against hepatitis B [9] . The immunodeficiency is based on reduced T cell activating capabilities of the accessory cells, mainly the monocytes [10] , and the costimulatory system of the B71CD28 pathway seems to be involved [ii] . Until now a role for the overproduction of soluble mediators by monocytes has not been proven. The in vivo immune response of dialysis patients against hepatitis B vaccination correlates well with cellular function in vitro [10] . By classifying the patients into nonresponders and responders to a hepatitis B vaccination we show that there is a strong relation between overproduction of monokines upon LPS stimulation and the clinical state of immune responsiveness.
These results focus further interest on regulatory mechanisms of monokine secretion. Interleukin-lO was first identified and cloned as a cytokine synthesis inhibitory factor (CSIF) [12] . One of its major effects is the inhibition of the production of IL-i, IL-6 and TNFcs by activated monocytes/macrophages [13] , IL-tO can be induced by stimuli similar to those that induce high cytokine secretion in dialysis patients and an autoregulatory role for monokine induction has been shown [14] . We show here that an enhanced production of IL-b in cells from responders to hepatitis B vaccination effectively controls monokine overproduction.
Methods Patients
Twenty-eight patients on chronic hemodialysis using cuprophane dialyzers and bicarbonate dialysate for a mean time of 4.5 hours three times a week were studied. Dialyzers were not reused. None of the patients took medication with immunosuppressive effects including the regular intake of cyclooxygenase inhibitors. Patients were classified as responders or nonresponders according to the efficacy of a standard vaccination against hepatitis B. Antibody titers were determined after four injections of 40 jig hepatitis B vaccine (Engerix B, Smith Kline Dauelsberg, Göttingen, Germany) at 0, 1, 6 and 9 months. Responders had iO lU/mi at two determinations between months 9 and 12, nonresponders had C 10 lU/mI. IL-6 5'-ATGAACTCCTITCTCCACAAGCGC-3' 5'-GAAGAGCCCTCAGGCTGGACTG-3' 628 [18] TNFs 5'-AGAGGGAAGAGITCCCCAGGGAC-Y 5'-TGAGTCGGTCACCCTTCTCCAG-3' 450 [14] IL-lO 5'-CTGAGAACCAAGACCCAGACATCAAGG-3'
5'-CAATAAGGmCTCAAGGGGCTGGGTC-3'
352 [19] The control group consisted of 14 healthy individuals from our laboratory personnel.
Cell preparation and culture conditions Twenty ml of heparinized venous blood were obtained from patients immediately before the start of hemodialysis. Mononuclear cells were preparated on a Ficoll density gradient (Biochrom, Berlin, Germany). Cells were cultured at 1 X 106 cells/ml in RPMI 1640 (Biochrom) containing 5% fetal calf serum, 2 mM glutamine and 50 J.Lg/ml gentamicin. Cells were stimulated with LPS (S. typhimurium, Sigma, Deisenhofen, Germany) at a concentration of 100 ng/ml. Recombinant human IL-b (Genzyme, Cambridge, MA, USA) was used at a final concentration of 10 nglml unless otherwise indicated. Supernatants were harvested after 24 hours of stimulation and frozen at -20°C. Experiments were always performed on a responder, a nonresponder and a control person on the same day. Anti-IL-lO JES3-9D7 (Pharmingen, San Diego, CA, USA) was used at a final concentration of 10 p.g/ml.
Detection of IL-i 13, IL-6 and TNFs IL-113, IL-6 and TNFa were measured using commercial ELISA test systems. The following ELISA kits were used: Quantikine IL-1/3 (R&D Systems, Minneapolis, MN, USA; detection limit 4.5 pg/ml), Quantikine IL-6 (R&D Systems; detection limit 3.5 pg/mI) and TNFa ELISA (Hofmann La-Roche, Basel, Switzerland). All supernatants were tested in duplicate and in appropriate dilutions, and all samples for a given assay were tested simultaneously.
Bioassay for IL-b
Human IL-b was detected using a specific bioassay which has been recently described [151. Proliferation of the murine mast cell line D36 in the presence of murine IL-4 is strictly dependent on the presence of murine or human IL-b. D36 cells were used at 3 x iO per well with 2 U/ml of murine IL-4 (provided by C. HUls, Mainz) and 50 p3/well of the supernatant to be tested in a final volume of 100 p1/well in round bottom microtiter plates (Greiner, NUrnberg, Germany). After 18 to 20 hours, 0.2 .tCi of 3H-thymidine were added to each well and incubated for another 16 hours. Finally the cells were harvested and counted in a liquid scintillation counter (BetaPlate 1205, Pharmacia, Sweden). Results were expressed as U/mI with one unit defined as the amount of IL-b that induces half-maximal proliferation of D36 cells. One U/ml was equal to 1 nglml of recombinant human IL-b (Genzyme). The detection limit was 0.3 U/mI.
Extraction and reverse transcription of mRNA For the detection of mRNA PBMC were stimulated at 1 X 106/ml for 24 hours with LPS. Reverse transcription and PCR were performed as previously described [8, 16] . Briefly, the cell pellet was lysed with 4 M guanidinium thiocyanate, 0.5 m sodium citrate (pH 7.0), 0.5% sarcosyl, 20 mM 2-mercaptoethanol and 0.1 M sodium acetate (pH 4.2). RNA was extracted using equal parts of H20-saturated phenol and chioroform/isoamylalcohol (24:1) . RNA was precipitated from the aqueous phase by 2-propanol and the pellet was washed in 75% and 100% ethanol. Semiquantitative PCR PCR was performed using the following conditions: 10 al of cDNA were amplified in a final volume of 100 .tl containing Tris HC1 20 mivi, KC1 50 ms, MgCl2 2.5 m'vi, dNTPs 40 M each nucleotide, and 400 nM each primer. The mixture was heated to 96°C for three minutes for denaturation and temperature was adjusted to 76°C on the thermal cycler (Omnigene, Hybaid Ldt., Teddington, UK) before 1.5 U of Taq polymerase (Gibco) were added. PCR was performed for three cycles at 96°C for 40 seconds, 58°C for 30 seconds, 72°C for 60 seconds followed by 30 to 36 cycles with an annealing temperature of 54°C. After 20 to 26 cycles an aliquot of 10 .tl was taken from the mixture every two cycles. PCR product was visualized on 1.5% agarose gels stained with ethidium bromide. Semiquantitative description of mRNA levels was based on the number of cycles that lead to a visible product in the gel [16] . Additional experiments showed that after a predilution of 1:16 of a known concentration of cDNA four more cycles were required to obtain a visible band of PCR product. Cytoplasmic 13-actin was used as a standard and cDNA was prediluted according to the bands appearing for this mRNA before the PCR on cytokines was performed. Primer sequences and expected product lengths are given in Table 1 .
Statistics
Calculations were performed using the InStat scientific software (Graphpad, San Diego, CA, USA). Results are given as raw data and mean or as mean standard deviation. Significance of the differences in cytokine concentrations was calculated by ANOVA and Bonferroni's multiple comparisons test. Correlations were detected by linear regression analysis.
Results (Fig. 1D ) than nonresponders who were not different from controls. Secretion of IL-1f3 did not differ between the groups (Fig. 1A) . Although the values for this cytokine were not beyond the normal range, those patients with the higher levels of IL-6 and TNFa also had the highest values for IL-1f3 (not shown). This relation could not be found in the controls, probably due to the lower cytokine concentrations in this group. The levels of IL-6 and TNFt were correlated in all three groups studied (not shown).
Corresponding to the high secretion of monokines a high level of transcription of mRNA for IL-6 was found in nonresponders whereas responders did not differ from controls, The level of mRNA expression for TNFa was also enhanced in nonresponders while being normal in responders. A typical example of the findings is shown in Figure 2 . Expression of mRNA was determined in 6 controls and 12 patients. Overexpression of IL-6 and TNFa mRNA was found in all nonresponders studied. In 5 of 6 responders the levels of mRNA specific for IL-b tended to be higher than in nonresponders and controls hut this was not as impressive as the differences for IL-6 (Fig. 2) . As the level of transcription for IL-b was much lower than that for IL-6 the difference between responders and nonresponders is difficult to be shown by semiquantitative PCR. The overexpression in most of the responders studied may indicate a difference in transcriptional regulation for this cytokine.
Patients with high secretion of IL-6 in vitro also have high serum levels of IL-6 in vivo
To demonstrate that the in vitro monokine secretion is relevant to the in vivo situation serum levels of IL-1f3, IL-6 and TNFa were determined. IL-6 was detectable in the serum of only 2 of 14 controls. Pre-dialysis serum levels of IL-6 could be detected in 12 of 14 nonresponder patients (mean 7.96 4.7 pg/mi) and in 8 of 14 responders (mean 3.89 3.8 pg/mi, nonresponder vs. responder not significant). The patients with the highest in vitro levels of 1L-6 upon LPS stimulation also had the highest serum IL-6 in supernatant, ng/ml sion was achieved in both patient's groups at a concentration of 2.5 ng/ml while a concentration of 1 ng/ml IL-b was sufficient to reduce monokine production in the control group (Fig. 5) . The levels of IL-6 (r2 = 0.62, P < 0.00 1, Fig. 3 ). IL-113 and TNFa were found inconsistently in the sera of patients and controls at levels near to the detection limits of the ELISAs. Significant differences between the groups could not be demonstrated (data not shown).
Production of IL-b is negatively correlated with secretion of IL-6 in responder patients As IL-b is a down-regulatory factor for monokine secretion we examined the individual relation of IL-b and IL-6 in the culture supernatants. In the responder group patients with higher levels of IL-JO upon LPS stimulation have lower levels of IL-6 (Fig. 4 , r2 = 0.54, P < 0.01). In nonresponders and controls no such correlation between these cytokines could be found. This is mainly due to the fact that the concentrations of IL-b in the supernatants of these cells were lower than in many of the responder patients. These results may indicate an inhibitory effect of this protein on the production of IL-6. This assumes intact effector mechanisms for IL-b in dialysis patients. and the requirement of higher concentrations in hemodialysis patients. mRNA for IL-6 also was downregulated by recombinant IL-b while the transcription for f3-actin was unaffected (Fig. 6 ). This shows a specific effect of IL-b on the cytokines rather than an action as an unspecifically toxic agent.
Production of IL-6 in responders reaches levels of nonresponders after blockade of IL-lO by monoclonal antibody The production of IL-6 upon stimulation by LPS was compared in the absence and presence of a blocking monoclonal antibody against human IL-b. Without this antibody cells from nonresponders produced more than twice the amount of IL-6 compared to cells from controls. Cells from responders showed an intermediate production. Blocking of IL-b in this assay lead to an enhanced production of IL-6 in all groups including the controls. But while controls remained at about 25 ng/ml the secretion of IL-6 in cells from responders reached the same level as that of nonresponders (Fig. 7) .
Discussion
In the present study we show that PBMC obtained from hemodialysis patients 42 hours after the last dialysis treatment produce high amounts of monokines upon stimulation by LPS. Unlike recent studies investigating the secretion of IL-6 [4] or TNFa [5] by otherwise unstimulated PBMC immediately after dialysis we focused on the long-term alterations arising from uremia and its treatment, as these might be more important for the defect of immune defense commonly seen in the patients. The immune defect of hemodialysis patients is characterized by a reduced T cell activation resulting in a low production of IL-2 [10] while the expression of IL-2 receptors is high [20] . The basis therefore is a defect of the accessory cells [10] that have a reduced capability to provide costimulatory signals for T cell activation. Costimulatory signals arise from surface molecules of the accessory cell or from its soluble mediators, Recently we could show a role for the surface molecule B7 on monocytes [11] . Whether or rhiL-lO, ng/ml not soluble mediators are important for the reduced T cell activation has not been shown yet. From theoretical studies this is possible as a suppressive effect of TNFa on the IL-2 dependent clonal expansion of T cells is known [21] . Additionally IL-i and IL-6 directly enhance the expression of IL-2 receptors on T cells [22] and a correlation between high levels of IL-6 and soluble IL-2 receptor has been shown in HIV patients [23] . Given these effects high levels of TNFs and IL-6 might very well contribute to the characteristics of the immune defect in dialysis patients.
A good indicator for the grade of immunodeficiency of a patient is the in vivo response after vaccination against hepatitis B [9] . We thus compared responders and nonresponders to hepatitis B vaccination concerning their monokine profile. Upon stimulation by LPS a clear difference between the two patient groups concerning the secretion of IL-6 and TNFa appeared. Cells from nonresponders to hepatitis B vaccination produced more of these cytokines than responders who mainly behaved like healthy controls. This was confirmed by an overexpression of mRNA for IL-6 and TNFa in the nonresponder patients. The strong relation between the in vivo immune status of the patients and the in vitro monokine secretion indicates a possible pathogenetical role for the immune defect of these patients. High secretion of TNFa by cells from dialysis patients after stimulation by LPS has been shown before [5] . In contrast Friedlander and coworkers [24] found an impaired production of IL-lp and TNFa. Secretion of IL-6 tended to be higher in their patients although this was not significant. It is difficult to compare these results with ours since bioassays for TNFa and IL-6 were used that may be influenced by soluble inhibitors of the cytokines. Moreover, we can show a heterogeneity of the dialysis patients and we do not know about the clinical immune status of the patients in that study. [3], IL-6 [2, 25] and TNFcs [3, 5] . While IL-i and IL-6 remain stable [2, 3, 25] a further increase was noted for serum TNFa during the dialysis procedure [5, 7] , We only detected significantly high serum levels for IL-6. This may be related to the presence of varying amounts of inhibitors for TNFa [26] or IL-i [271 in the serum of dialysis patients. The overproduction of monokines by cells from nonresponders was contrasted by higher levels of interleukin-lO from cells of responder patients. IL-b was measured because this substance, originally referred to as cytokine synthesis inhibitory factor (CSIF) [12] , is an interesting candidate for the regulation of monokine secretion. The cytokine can be produced by a number of different cells, among them mainly monocytes, B cells, and T cells [13] . The most important effects of IL-b are those directed at the antigen presenting cell. At lower concentrations the production of monokines is down-regulated. At higher concentrations (100 UIml) the antigen presenting function and class II molecule expression are inhibited as well [14] . IL-b can be induced in monocytes by LPS at the same concentrations that lead to the secretion of IL-i, IL-6 and TNF. Recently an autoregulatory role of IL-b on monocyte function has been demonstrated [14] .
The individual coincidence of high levels of TNFa and IL-6 can be explained by the induction of IL-6 as an effect of TNFn [28] .
The reciprocal relation between IL-6 and IL-b, although not proving a causal relationship, indicates that the elevation of IL-b might be a counterregulatory mechanism to control the monokine overproduction induced by uremia.
This hypothesis assumes that the control of monokine secretion by IL-b is effective in dialysis patients. We could achieve a nearly complete suppression of IL-6 by the addition of recombinant IL-b to the cultures in all study groups. Kinetic analysis showed that the concentrations of IL-b necessary to control the overproduction of IL-6 in the patient's cells are within the range of concentrations usually detected in culture supernatants of stimulated cells. The doses needed for half maximal suppression of in the patient groups was about 2.5-fold the dosis of the control group. On the other hand a blockade of IL-b in the supernatant of stimulated cells by monoclonal antibodies lead to an increased secretion of IL-6 in the responder as well as the nonresponder group while the production in the control group remained much lower. Thus IL-b can be addressed as the causal factor in controlling monokine secretion in responder patients.
As discussed above it is highly probable that this effect is causally relevant for the clinical immune defect. Additionally IL-b may directly inhibit the secretion of prostaglandins that act suppressively on T cells. Furthermore, IL-b exerts directly stimulating effects on B cells and might thus increase the production of specific antibodies in vivo. This could be relevant for our criterion of in vivo immune function, the response to hepatitis B vaccination.
In conclusion, the enhanced monokine production by PBMC of hemodialysis patients is correlated with the in vivo immune status of the patients. Therefore it may contribute to the reduced T cell activating capabilities of accessory cells from dialysis patients. An It is effective in patients as well as in controls and a moderate increase in its secretion is sufficient to normalize monokine levels. Blocking the IL-lO effect leads to levels of IL-6 in the responder group which compare to those of nonresponders. These results support the notion that the responder dialysis patients can use an elevated secretion of IL-b for down-regulation of cytokine overproduction while nonresponders seem to lack this mechanism.
